A baseline model including quantitative anti-HBc to predict response of peginterferon in HBeAg-positive patients.

Objective: to explain anti-HBc is a new predictor of peginterferon treatment response. Type of research: clinical trial. Method of data collection: Serum samples were collected every 12 weeks, and were tested. Type of data: clinical data.

研究目标：阐明乙型肝炎核心抗体（anti-HBc）是聚乙二醇干扰素治疗应答的新型预测因子。研究类型：临床试验。数据收集方法：每12周采集血清样本并进行检测。数据类型：临床数据。